What are the most valued startups in the synthetic biology market?

Last updated: 13 July 2026

Download our beautiful pitch about the synthetic biology market

market research pitch 2026 statistics synthetic biology market

In our synthetic biology market deck, you will find everything you need to understand the market

This page tracks the most valuable startups in the synthetic biology market, from DNA synthesis and gene editing to precision fermentation, engineered materials, and laboratory infrastructure.

We update this ranking every month to reflect public market movements, new funding rounds, acquisitions, and revised private-company estimates.

The latest data shows a diverse market where a small group of major platforms captures a large share of total valuation, while many emerging companies remain below the $500 million level.

And if you want to better understand this new industry, you can download our pitch covering the synthetic biology market.

A quick summary table

Metric Value
Most valuable synthetic biology startup Benchling, estimated at $4.5B–$6.5B
Second most valuable synthetic biology startup Twist Bioscience, valued at $5.2B
Median synthetic biology startup valuation Approximately $220M–$240M
Share of synthetic biology valuation captured by the top 10 Approximately 50%
Top synthetic biology valuation versus median Approximately 24 times higher
Median valuation-to-capital-raised ratio Approximately 2 times
Synthetic biology startups valued at $1B+ 11 startups based on valuation midpoints
Market map chart showing top companies and startups in the synthetic biology market

This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market

Top startups in the synthetic biology market ranked by valuation

Here is an updated table that ranks the top startups in the synthetic biology market based on their latest reported or estimated valuations.

If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the synthetic biology market.

# Startup Name What They Do Current Valuation ($) Valuation Confidence Level Valuation Type Evidence Status Total Funding ($) Funding Confidence Level
1 Benchling Biotech R&D cloud software $4.5B–$6.5B Partial Confidence Revenue or ARR Multiple Estimate Estimated $420M Strong Confidence
2 Twist Bioscience DNA synthesis platform $5.2B Full Confidence Public Market Cap Observed $300M Strong Confidence
3 Generate Biomedicines AI-designed protein therapeutics $2.1B Full Confidence Public Market Cap Observed $1.1B Strong Confidence
4 Solugen Bio-based industrial chemicals $1.8B–$2.3B Strong Confidence Announced Private Round Valuation Estimated $600M Strong Confidence
5 Pivot Bio Microbial crop nutrients $1.7B–$2.1B Partial Confidence Comparables-Based Estimate Estimated $600M Strong Confidence
6 ArsenalBio Programmable cancer cell therapies $1.2B–$1.8B Partial Confidence Implied Valuation from Raise Estimated $630M Full Confidence
7 Perfect Day Animal-free dairy proteins $1.2B–$1.8B Partial Confidence Comparables-Based Estimate Estimated $1.0B Strong Confidence
8 Tune Therapeutics Epigenome-editing therapeutics $1.1B–$1.7B Strong Confidence Implied Valuation from Raise Implied $215M Full Confidence
9 EvolutionaryScale AI protein generation models $1.0B–$1.5B Partial Confidence Implied Valuation from Raise Implied $142M Full Confidence
10 Spiber Fermented protein materials $1.0B–$1.3B Partial Confidence Announced Private Round Valuation Estimated $491M Strong Confidence
11 Asimov Genetic design and biomanufacturing $900M–$1.3B Partial Confidence Implied Valuation from Raise Estimated $205M Strong Confidence
12 Profluent AI-designed proteins and gene editors $700M–$1.1B Strong Confidence Implied Valuation from Raise Implied $150M Full Confidence
13 Mammoth Biosciences CRISPR therapeutics and diagnostics $700M–$1.0B Partial Confidence Comparables-Based Estimate Estimated $263M Strong Confidence
14 Impossible Foods Plant-based meat alternatives $427M–$1.2B Low Confidence Proxy-Based Estimate Estimated $2.0B Strong Confidence
15 Arbor Biotechnologies Gene-editing therapeutics platform $550M–$850M Strong Confidence Implied Valuation from Raise Implied $305M Partial Confidence
16 Chroma Medicine Epigenetic-editing medicines $500M–$850M Partial Confidence Comparables-Based Estimate Estimated $260M Strong Confidence
17 Obsidian Therapeutics Regulatable engineered cell therapies $550M–$800M Partial Confidence Comparables-Based Estimate Estimated $326M Strong Confidence
18 Tessera Therapeutics Gene-writing medicines $550M–$750M Partial Confidence Comparables-Based Estimate Estimated $610M Strong Confidence
19 Cradle AI protein engineering software $500M–$750M Partial Confidence Implied Valuation from Raise Implied $103M Strong Confidence
20 DNA Script Desktop enzymatic DNA synthesis $550M–$700M Partial Confidence Comparables-Based Estimate Estimated $315M Strong Confidence
21 Ginkgo Bioworks Cell-programming platform $592M Full Confidence Public Market Cap Observed $2.5B Strong Confidence
22 Formo Fermented dairy alternatives $410M–$760M Partial Confidence Implied Valuation from Raise Implied $116M Full Confidence
23 Hexagon Bio Microbial-genome drug discovery $450M–$700M Low Confidence Comparables-Based Estimate Estimated $185M Partial Confidence
24 Strand Therapeutics Programmable mRNA cancer therapies $500M–$600M Strong Confidence Announced Private Round Valuation Observed $211M Partial Confidence
25 The EVERY Company Animal-free egg proteins $370M–$690M Strong Confidence Implied Valuation from Raise Implied $287M Strong Confidence
26 bit.bio Programmed human cell products $450M–$600M Strong Confidence Revenue or ARR Multiple Estimate Estimated $233M Partial Confidence
27 Genomatica Renewable industrial chemicals $420M–$620M Partial Confidence Revenue or ARR Multiple Estimate Estimated $388M Partial Confidence
28 GRO Biosciences Expanded-code protein therapeutics $400M–$600M Partial Confidence Implied Valuation from Raise Implied $87M Partial Confidence
29 Octant Multiplexed drug-discovery platform $350M–$600M Low Confidence Comparables-Based Estimate Estimated $115M Strong Confidence
30 Ansa Biotechnologies Long synthetic DNA manufacturing $360M–$540M Strong Confidence Implied Valuation from Raise Implied $132M Strong Confidence
31 Liberation Labs Precision-fermentation manufacturing $350M–$550M Partial Confidence Implied Valuation from Raise Implied $20M Partial Confidence
32 Constructive Bio Synthetic genomes and biomolecules $350M–$500M Partial Confidence Implied Valuation from Raise Implied $75M Strong Confidence
33 Geltor Animal-free collagen proteins $350M–$500M Partial Confidence Proxy-Based Estimate Estimated $137M Strong Confidence
34 Cellino Automated cell-therapy manufacturing $300M–$500M Partial Confidence Comparables-Based Estimate Estimated $96M Strong Confidence
35 Onego Bio Animal-free egg proteins $275M–$460M Partial Confidence Implied Valuation from Raise Implied $57M Partial Confidence
36 MycoWorks Mycelium leather materials $250M–$450M Partial Confidence Implied Valuation from Raise Estimated $187M Partial Confidence
37 Culture Biosciences Cloud biomanufacturing platform $280M–$400M Strong Confidence Announced Private Round Valuation Estimated $101M Strong Confidence
38 Checkerspot Fermented oils for materials $280M–$380M Partial Confidence Proxy-Based Estimate Estimated $109M Strong Confidence
39 Remilk Animal-free dairy proteins $275M–$375M Strong Confidence Announced Private Round Valuation Estimated $131M Full Confidence
40 Nobell Foods Plant-produced dairy proteins $240M–$380M Low Confidence Comparables-Based Estimate Estimated $100M Partial Confidence
41 64x Bio High-yield biomanufacturing cell lines $220M–$380M Low Confidence Revenue or ARR Multiple Estimate Estimated $60M Partial Confidence
42 Zymergen Bio-based materials platform $300M Full Confidence Acquisition Value Observed $900M Strong Confidence
43 Standing Ovation Animal-free casein proteins $210M–$310M Strong Confidence Implied Valuation from Raise Implied $45M Strong Confidence
44 AMSilk Biofabricated silk proteins $190M–$310M Partial Confidence Implied Valuation from Raise Implied $104M Partial Confidence
45 Amyris Synthetic ingredients platform $200M–$300M Low Confidence Proxy-Based Estimate Estimated $1.2B Strong Confidence
46 Locus Biosciences CRISPR-engineered antimicrobial phages $180M–$300M Low Confidence Implied Valuation from Raise Implied $59M Partial Confidence
47 Modern Meadow Biofabricated leather materials $180M–$280M Partial Confidence Announced Private Round Valuation Estimated $184M Partial Confidence
48 Vivici Precision-fermented dairy proteins $170M–$280M Partial Confidence Implied Valuation from Raise Implied $34M Partial Confidence
49 Debut Biotech beauty ingredients platform $180M–$260M Strong Confidence Implied Valuation from Raise Implied $119M Partial Confidence
50 Verley Precision-fermented whey proteins $160M–$250M Strong Confidence Implied Valuation from Raise Implied $50M Strong Confidence
51 BioPhero Fermented insect-control pheromones $200M Full Confidence Acquisition Value Observed $21M Full Confidence
52 Evonetix Semiconductor-based DNA synthesis $140M–$240M Low Confidence Comparables-Based Estimate Estimated $66M Strong Confidence
53 Basecamp Research Biodiversity-based AI drug discovery $160M–$210M Partial Confidence Comparables-Based Estimate Estimated $85M Partial Confidence
54 Eligo Bioscience Microbiome-targeted gene editing $140M–$220M Low Confidence Implied Valuation from Raise Implied $53M Strong Confidence
55 All G Precision-fermented dairy proteins $120M–$220M Partial Confidence Proxy-Based Estimate Estimated $30M Strong Confidence
56 Emerald Cloud Lab Remote automated cloud laboratory $120M–$220M Low Confidence Comparables-Based Estimate Estimated $40M Low Confidence
57 Colorifix Biological textile dyes $125M–$200M Strong Confidence Implied Valuation from Raise Implied $44M Strong Confidence
58 Arzeda Industrial proteins and enzymes $140M–$170M Strong Confidence Proxy-Based Estimate Estimated $91M Strong Confidence
59 Shiru AI-designed functional proteins $110M–$200M Partial Confidence Implied Valuation from Raise Implied $37M Full Confidence
60 Opentrons Open laboratory automation robots $120M–$180M Partial Confidence Comparables-Based Estimate Estimated $271M Partial Confidence
61 Ecovative Mycelium materials platform $110M–$180M Partial Confidence Implied Valuation from Raise Implied $131M Partial Confidence
62 Strateos Robotic cloud laboratory platform $110M–$180M Low Confidence Comparables-Based Estimate Estimated $99M Partial Confidence
63 TurtleTree Cell-cultured dairy ingredients $100M–$180M Partial Confidence Proxy-Based Estimate Estimated $39M Strong Confidence
64 Synthace Biology experiment automation software $110M–$160M Partial Confidence Revenue or ARR Multiple Estimate Estimated $73M Strong Confidence
65 Inscripta Industrial biomanufacturing technology $80M–$160M Low Confidence Acquisition Value Estimated $495M Partial Confidence
66 ZymoChem Bio-based specialty materials $90M–$150M Partial Confidence Implied Valuation from Raise Implied $25M Strong Confidence
67 Rubi Laboratories Carbon-to-materials biotechnology $90M–$140M Partial Confidence Comparables-Based Estimate Estimated $26M Partial Confidence
68 Imagindairy Animal-free milk proteins $75M–$140M Partial Confidence Implied Valuation from Raise Implied $28M Strong Confidence
69 Eden Brew Animal-free dairy proteins $80M–$130M Partial Confidence Implied Valuation from Raise Implied $23M Strong Confidence
70 Better Dairy Specialized dairy proteins $70M–$125M Partial Confidence Comparables-Based Estimate Estimated $24M Full Confidence
71 New Culture Animal-free cheese casein $60M–$120M Low Confidence Comparables-Based Estimate Estimated $29M Partial Confidence
72 String Bio Methane-based biomanufacturing platform $70M–$110M Partial Confidence Revenue or ARR Multiple Estimate Estimated $24M Full Confidence
73 Enduro Genetics Improves industrial bioproduction yields $65M–$105M Partial Confidence Implied Valuation from Raise Implied $12M Partial Confidence
74 Synthego CRISPR genome engineering tools $50M–$100M Partial Confidence Acquisition Value Estimated $460M Strong Confidence
75 Volta Labs Genomics sample-preparation automation $60M–$90M Low Confidence Revenue or ARR Multiple Estimate Estimated $33M Partial Confidence
76 Huue Bioengineered sustainable indigo dye $55M–$90M Low Confidence Proxy-Based Estimate Estimated $17M Full Confidence
77 Lygos Sustainable specialty chemicals $45M–$85M Low Confidence Comparables-Based Estimate Estimated $41M Partial Confidence
78 PILI Bio-based industrial colorants $50M–$80M Partial Confidence Revenue or ARR Multiple Estimate Estimated $25M Partial Confidence
79 Tierra Biosciences Cell-free protein synthesis platform $50M–$80M Partial Confidence Implied Valuation from Raise Implied $17M Partial Confidence
80 AlgiKnit / Keel Labs Seaweed-derived textile fibers $45M–$70M Partial Confidence Revenue or ARR Multiple Estimate Estimated $17M Strong Confidence
81 Melt&Marble Precision-fermented fats and oils $43M–$68M Strong Confidence Implied Valuation from Raise Implied $15M Full Confidence
82 Change Foods Animal-free cheese proteins $35M–$75M Low Confidence Implied Valuation from Raise Implied $15M Strong Confidence
83 Ribbon Biolabs Custom long DNA synthesis $35M–$55M Partial Confidence Comparables-Based Estimate Estimated $20M Strong Confidence
84 Sherlock Biosciences CRISPR molecular diagnostic tests $30M–$60M Low Confidence Acquisition Value Estimated $111M Strong Confidence
85 Solena Materials AI-designed protein fibers $35M–$50M Strong Confidence Implied Valuation from Raise Implied $11M Full Confidence
86 Octarine Bio Fermented pigments and bioingredients $30M–$45M Partial Confidence Implied Valuation from Raise Implied $14M Partial Confidence
87 Michroma Fungi-based food colorants $24M–$42M Low Confidence Comparables-Based Estimate Estimated $7M Partial Confidence
88 Protera AI-designed functional proteins $25M–$40M Low Confidence Proxy-Based Estimate Estimated $16M Strong Confidence
89 Senti Biosciences Gene-circuit cell therapies $31M Full Confidence Public Market Cap Observed $502M Strong Confidence
90 Catalog DNA data storage computing $15M–$35M Low Confidence Acquisition Value Estimated $54M Strong Confidence
91 Molecular Assemblies Enzymatic DNA synthesis technology $10M–$30M Low Confidence Acquisition Value Estimated $64M Strong Confidence
92 Wild Microbes Engineered microbes for manufacturing $15M–$23M Partial Confidence Revenue or ARR Multiple Estimate Estimated $3M Strong Confidence
93 TeselaGen Synthetic-biology design software $12M–$20M Low Confidence Revenue or ARR Multiple Estimate Estimated $2M Low Confidence
94 Bolt Threads Biomaterials and beauty ingredients $8M–$15M Strong Confidence Public Market Cap Observed $500M Strong Confidence
95 Viridos Algae-based sustainable fuels $5M–$15M Low Confidence Acquisition Value Estimated $100M Partial Confidence
96 Synlogic Engineered bacterial medicines $5M–$9M Low Confidence Public Market Cap Observed $151M Partial Confidence
97 Daisy Lab Precision-fermented dairy proteins $4M–$8M Low Confidence Implied Valuation from Raise Implied $1M Strong Confidence
98 Motif FoodWorks Plant-based ingredient biotechnology $0M–$5M Strong Confidence Proxy-Based Estimate Estimated $344M Full Confidence
Chart comparing the 2026 size of the synthetic biology market with other markets of similar size

This chart, featured in our synthetic biology market deck, compares the 2026 size of the synthetic biology market with other markets of similar size

Key valuation trends in the synthetic biology market

Insights

  • The top 10 synthetic biology startups capture approximately half of the total midpoint valuation in the ranking, showing that market value is concentrated even though the sector includes almost 100 companies.
  • Twist Bioscience has a market capitalization of approximately 17 times its reported funding, making the DNA synthesis company one of the clearest examples of capital-efficient value creation in synthetic biology.
  • Tune Therapeutics and Profluent hold approximately $2.3 billion in combined midpoint valuation after raising $365 million, which highlights the premium assigned to programmable biology and AI-enabled protein design.
  • Ginkgo Bioworks has raised approximately $2.5 billion but carries a market capitalization of $592 million, meaning the public market values the cell-programming company at less than one-quarter of invested capital.
  • Standing Ovation and Verley have raised only $95 million combined but carry approximately $465 million in aggregate midpoint valuation, showing continued demand for specialized precision-fermented dairy proteins.
  • BioPhero's $200 million acquisition price was approximately 9.5 times its reported funding, which suggests focused agricultural biotechnology assets can produce attractive strategic exit multiples.
  • Culture Biosciences and Ansa Biotechnologies have approximately $790 million in combined midpoint valuation from $233 million of funding, showing that synthetic biology infrastructure can scale without consumer-level capital requirements.
  • Colorifix, Melt&Marble, and Solena Materials have raised approximately $70 million combined while reaching about $261 million in midpoint valuation, highlighting capital-efficient opportunities in biological dyes, fats, and protein materials.
  • Senti Biosciences, Bolt Threads, and Motif FoodWorks raised approximately $1.35 billion combined but retain only about $45 million in aggregate midpoint value, illustrating the downside of expensive commercialization strategies.
  • The strongest synthetic biology outcomes span DNA synthesis, therapeutics, industrial chemicals, food proteins, laboratory infrastructure, and engineered materials, so value creation is not limited to one business model.
Chart showing how Twist Bioscience is capturing share in the synthetic biology market

This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology

A few word about our methodology

As you can see, we built a database that ranks startups in the synthetic biology market based on their current valuation.

Estimating synthetic biology startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.

To build this ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.

Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed synthetic biology companies, or official acquisition prices.

When a synthetic biology company is publicly listed, we use its current market capitalization as the reference valuation.

If a company was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.

When a synthetic biology startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.

In some cases, we also estimate valuations using operating metrics such as revenue, ARR, manufacturing capacity, commercial partnerships, or customer traction, combined with valuation multiples from comparable synthetic biology companies.

When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, scientific progress, production milestones, or product traction.

All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.

We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.

Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.

Because valuation data is not always fully public, each synthetic biology startup in the ranking is assigned a confidence level based on the reliability, recency, and consistency of the available evidence.

Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.

When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.

This reflects how we conduct all our research, including the work behind our report covering the synthetic biology market.

In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.

If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.

Finally, know that we update the dataset once per month, so come back here if you need fresh information.

Chart showing the projected CAGR of the synthetic biology market

This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups

Related blog posts

- The most recent news in synthetic biology

- The most recent funding news in synthetic biology

- The latest changes in the synthetic biology market

- The evolution of funding activity in synthetic biology

- The main fundraising trends in synthetic biology

- How large is the synthetic biology market today?

- The full range of business models in synthetic biology

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.

Back to blog